TGFβ1 Polymorphisms Predict Distant Metastasis–Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy

Purpose Transforming growth factor (TGF) -β1 signaling is involved in cancer-cell metastasis. We investigated whether single nucleotide polymorphisms (SNPs) at TGFβ1 were associated with overall survival (OS) and distant metastasis-free survival (DMFS) in patients with non-small cell lung cancer (NSCLC) treated with definitive radiotherapy, with or without chemotherapy. Methods We genotyped TGFβ1 SNPs at rs1800469 (C–509T), rs1800471 (G915C), and rs1982073 (T+29C) by polymerase chain reaction-restriction fragment length polymorphism in blood samples from 205 NSCLC patients who had had definitive radiotherapy at one institution in November 1998–January 2005. We also tested whether the TGF-β1 rs1982073 (T+29C) SNP affected the migration and invasion of A549 and PC9 lung cancer cells. Results Median follow-up time for all patients was 17 months (range, 1–97 months; 39 months for patients alive at the time of analysis). Multivariate analysis showed that the TGFβ1 rs1800469 CT/CC genotype was associated with poor OS (hazard ratio [HR] = 1.463 [95% confidence interval {CI} = 1.012–2.114], P = 0.043) and shorter DMFS (HR = 1.601 [95% CI = 1.042–2.459], P = 0.032) and that the TGFβ1 rs1982073 CT/CC genotype predicted poor DMFS (HR = 1.589 [95% CI = 1.009–2.502], P = 0.046) and poor brain MFS (HR = 2.567 [95% CI = 1.155–5.702], P = 0.021) after adjustment for age, sex, race, performance status, smoking status, tumor histology and volume, stage, receipt of concurrent radiochemotherapy, number of chemotherapy cycles, and radiation dose. Transfection with TGFβ1+29C (vs. +29T) stimulated the migration and invasion of A549 and PC9 cells, suggesting that TGFβ1+29C may be linked with increased metastatic potential. Conclusions TGFβ1 genotypes at rs1800469 and rs1982073 could be useful for predicting DMFS among patients with NSCLC treated with definitive radiation therapy. These findings require validation in larger prospective trials and thorough mechanistic studies.

[1]  M. Tatari,et al.  EMT as the ultimate survival mechanism of cancer cells. , 2012, Seminars in cancer biology.

[2]  H. Choy,et al.  Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Martha L. Slattery,et al.  Genetic Variation in the TGF-β Signaling Pathway and Colon and Rectal Cancer Risk , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[4]  M. Martel,et al.  Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  F. Tsai,et al.  Transforming growth factor-beta1 increases cell migration and beta1 integrin up-regulation in human lung cancer cells. , 2009, Lung cancer.

[6]  C. Onal,et al.  Prophylactic cranial irradiation in locally advanced non-small cell lung cancer: outcome of recursive partitioning analysis group 1 patients , 2008, Journal of experimental & clinical cancer research : CR.

[7]  Daoud Meerzaman,et al.  SMAD6 contributes to patient survival in non-small cell lung cancer and its knockdown reestablishes TGF-beta homeostasis in lung cancer cells. , 2008, Cancer research.

[8]  D. Katsaros,et al.  TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival , 2008, British Journal of Cancer.

[9]  Javier De Las Rivas,et al.  A novel lung cancer signature mediates metastatic bone colonization by a dual mechanism. , 2008, Cancer research.

[10]  G. Blobe,et al.  TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. , 2008, Carcinogenesis.

[11]  J. Curtis,et al.  The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer. , 2008, Lung cancer.

[12]  V. Budach,et al.  Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Caldito,et al.  The elderly with synchronous non-small cell lung cancer and solitary brain metastasis: does palliative thoracic radiotherapy have a useful role? , 2007, Lung cancer.

[14]  D. Larson,et al.  Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall‐cell lung cancer , 2007, Cancer.

[15]  R. Akhurst,et al.  TGF beta inhibition for cancer therapy. , 2006, Current cancer drug targets.

[16]  K. Tsuchida,et al.  Inhibitors of the TGF-β Superfamily and their Clinical Applications , 2006 .

[17]  S. Jakowlew.  Transforming growth factor-β in cancer and metastasis , 2006, Cancer and Metastasis Reviews.

[18]  H. Thierens,et al.  TGFbeta1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors. , 2006, International journal of radiation oncology, biology, physics.

[19]  J. Massagué,et al.  The logic of TGFβ signaling , 2006 .

[20]  G. Hoser,et al.  Elevated TGF-β1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer , 2006, Archivum Immunologiae et Therapiae Experimentalis.

[21]  So-Yeon Park,et al.  The polymorphism and haplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy. , 2005, International journal of radiation oncology, biology, physics.

[22]  Hongbing Shen,et al.  Functional Polymorphisms of Matrix Metalloproteinase-9 Are Associated with Risk of Occurrence and Metastasis of Lung Cancer , 2005, Clinical Cancer Research.

[23]  R. Stoika,et al.  Expression of mRNA coding for TGF-beta and its receptors in irradiated human breast carcinoma MCF-7 cells differing in their sensitivity to doxorubicin. , 2005, Experimental oncology.

[24]  J. Yarnold,et al.  TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  W. Guo,et al.  [Correlation of matrix metalloproteinase-3 polymorphism to genetic susceptibility and lymph node metastasis of non-small cell lung cancer]. , 2005, Ai zheng = Aizheng = Chinese journal of cancer.

[26]  Maria Werner-Wasik,et al.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial , 2004, The Lancet.

[27]  A. Balmain,et al.  A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[28]  H. Groen,et al.  Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[29]  X. Shu,et al.  Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study. , 2004, Cancer research.

[30]  H. Kato,et al.  Significance of expression of TGF-beta in pulmonary metastasis in non-small cell lung cancer tissues. , 2003, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[31]  J. Chang-Claude,et al.  A Transforming Growth Factorβ1 Signal Peptide Variant Increases Secretion in Vitro and Is Associated with Increased Incidence of Invasive Breast Cancer , 2003 .

[32]  L. Wakefield,et al.  TGF-β signaling: positive and negative effects on tumorigenesis , 2002 .

[33]  A. Brichet,et al.  Pronostic factors of synchronous brain metastases from lung cancer. , 2001, Lung cancer.

[34]  F. André,et al.  Patterns of relapse of N2 nonsmall‐cell lung carcinoma patients treated with preoperative chemotherapy , 2001, Cancer.

[35]  T. Tsushima,et al.  Transforming growth factor‐β1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma , 2001 .

[36]  T. Moody,et al.  TRANSFORMING GROWTH FACTOR-b1 AND ITS RECEPTORS IN HUMAN LUNG CANCER AND MOUSE LUNG CARCINOGENESIS , 2000, Experimental lung research.

[37]  A. Roberts.  TGF-β signaling from receptors to the nucleus , 1999 .

[38]  R. Clough,et al.  Plasma transforming growth factor‐β1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma , 1999, Cancer.

[39]  P. Hasleton,et al.  Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. , 1998, Transplantation.

[40]  L Gaspar,et al.  Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. , 1997, International journal of radiation oncology, biology, physics.

[41]  J. Little,et al.  Radio‐induced modulation of transforming growth factor β1 sensitivity in a p53 wild‐type human colorectal‐cancer cell line , 1996, International journal of cancer.

[42]  P. Rubin,et al.  Long‐term observations of the patterns of failure in patients with unresectable non‐oat cell carcinoma of the lung treated with definitive radiotherapy report by the radiation therapy oncology group , 1987, Cancer.

[43]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[44]  J. Massagué,et al.  The logic of TGFbeta signaling. , 2006, FEBS letters.

[45]  G. Hoser,et al.  Elevated TGF-beta1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer. , 2006, Archivum immunologiae et therapiae experimentalis.

[46]  K. Tsuchida,et al.  Inhibitors of the TGF-beta superfamily and their clinical applications. , 2006, Mini reviews in medicinal chemistry.

[47]  S. Jakowlew.  Transforming growth factor-beta in cancer and metastasis. , 2006, Cancer metastasis reviews.

[48]  J. Chang-Claude,et al.  A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. , 2003, Cancer research.

[49]  A. Näär,et al.  A component of the ARC/Mediator complex required for TGF beta/Nodal signalling. , 2002, Nature.

[50]  L. Wakefield,et al.  TGF-beta signaling: positive and negative effects on tumorigenesis. , 2002, Current opinion in genetics & development.

[51]  T. Tsushima,et al.  Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. , 2001, Cancer.

[52]  A. Balmain,et al.  TGF-beta signaling in tumor suppression and cancer progression. , 2001, Nature genetics.

[53]  T. Spector,et al.  Genetic control of the circulating concentration of transforming growth factor type beta1. , 1999, Human molecular genetics.

[54]  A. Roberts.  TGF-beta signaling from receptors to the nucleus. , 1999, Microbes and infection.

[55]  R. Komaki,et al.  Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. , 1998, International journal of radiation oncology, biology, physics.

[56]  J. Massagué.  TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[57]  R A Patchell,et al.  Brain metastases. , 1991, Neurologic clinics.

[58]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.